Activity Title: 2017 Virtual Symposium: Closing the Gap Created by Clinical Inertia: New Strategies for T2DM Treatment
Activity Format: Virtual Symposium
Program Description:
The prevalence of T2DM in the United States is 29.1 million and it is the seventh leading cause of death and a major cause of morbidity, including microvascular, macrovascular, cerebrovascular, and peripheral vascular disease complications. Clinicians face several challenges in helping patients with T2DM reach their glycemic goals, including an increasing armamentarium which gives rise to confusion regarding proper selection and sequence, multiple sets of available evidence-based guidelines, and “clinical inertia” – the failure to close the gap between best practice and the patient’s usual level of care. The goal of this symposium is to increase awareness among clinicians of the challenges in reaching T2DM glycemic targets, to review the clinical guidelines for T2DM treatment using an array of antihyperglycemic agents, and to present evidence on emerging basal insulin/GLP-1RA fixed-ratio combination products.
Estimated Time to Complete: 1.0 hours
Release Date: December 15, 2017
Expiration Date: December 15, 2018
Credit Type(s) Available: ACCME, CDR, ACPE, ANCC
Maximum Credits: 1.0
Provided By: This activity is jointly provided by Global Education Group and the Cardiometabolic Health Congress.
Commercial Supporter:
Supported by an educational grant from Sanofi US.
Intended Audience:
The educational design of this activity addresses the needs of US-based healthcare professionals, including: physicians (MDs), nurse practitioners (NPs), physician assistants (PAs), nurses, pharmacists (ACPE), dieticians (CDR), and other allied health professionals.
Educational Objectives:
Upon completion of this activity, participants should be able to:
- Outline the stepwise approach to T2DM treatment as recommended by current ADA/EASD and AACE/ACE guidelines
- List potential barriers to treatment escalation in T2DM and the role of clinical inertia in reaching glycemic targets
- Describe the complementary actions of basal insulin and GLP-1RA inhibitors in treating T2DM
- Identify the role of emerging fixed-ratio basal insulin/GLP-1RA products in the treatment of patients with T2DM
Faculty Information:
Robert H. Eckel, MD
- Professor of Medicine
- Division of Endocrinology, Metabolism and Diabetes
- Division of Cardiology
- Professor of Physiology and Biophysics
- Charles A. Boettcher II Chair in Atherosclerosis
- Director, T32 in Obesity and Cardiovascular Disease
- University of Colorado Anschutz Medical Campus
- Director, Lipid Clinic, University Hospital
- Aurora, CO
Consultant/Independent Contractor: Sanofi/Regeneron-Expert Witness
Yehuda Handelsman, MD
- Medical Director and Principal Investigator
- Metabolic Institute of America
- Tarzana, CA
Grant/Research Support: Amgen, AstraZeneca, BMS, BI, Grifols, Janssen, Lexicon, Merck, Novo Nordisk, Sanofi
Advisory/Consultant: Amarin, Amgen, AstraZeneca, BI, Eisai, Intarcia, Lilly, Janssen, Merck, Merck-Pfizer, Novo Nordisk, Regeneron, Sanofi
Speakers Bureau: Amarin, Amgen, AstraZeneca, BI-Lilly, Janssen, Merck, Novo Nordisk, Sanofi, Regeneron
Dr. Handelsman and his immediate family do not have ownership interest and/or stocks of any Pharmaceutical or device company.
Athena Philis-Tsimikas, MD
- Corporate Vice President
- Scripps Whittier Diabetes Institute
- San Diego, CA
Consultant/Independent Contractor: Advisory board on behalf of Scripps Health for Astra Zeneca, DexCom, Lilly, Novo Nordisk, Sanofi (no direct or indirect reimbursement to advisor)
Grant/Research Support: Janssen, Lilly, Novo Nordisk, Sanofi, (No direct or indirect reimbursement to researcher)
Stock Shareholder: Ionis, Gilead, Novo Nordisk, Esperion
Julio Rosenstock, MD
- Director, Dallas Diabetes and Endocrine Center
- Clinical Professor of Medicine
- University of Texas Southwestern Medical Center
- Dallas, TX
Consultant/Independent Contractor: Roche, Sanofi, Novo Nordisk, Eli Lilly, Daiichi Sankyo, AstraZeneca, Janssen, Boehringer-Ingelheim, Lexicon, and Intarcia
Grant/Research Support: Merck, Pfizer, Sanofi, Novo Nordisk, Roche, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Takeda, AstraZeneca, Janssen, Daiichi Sankyo, Lexicon, Boehringer-Ingelheim, and Intarcia
Disclosure of Conflicts of Interest:
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Provider Disclosures:
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Ashley Marostica, RN, MSN, has nothing to disclose.
Andrea Funk, has nothing to disclose.
Liddy Knight, has nothing to disclose.
Erin Franceschini, MS, has nothing to disclose.
Karin McAdams, has nothing to disclose.
Accreditation
Physician Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and CMHC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Credit Designation Statement(s):
Physician Credit Designation
Global Education Group designates this virtual activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
This activity includes 0.7 pharmacotherapy hours.
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation
Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. This is a knowledge based activity. Universal Activity Number (UAN): 0530-9999-17-448-H01-P
Dietician Accreditation Statement
Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.0 Continuing Professional Education units (CPEUs) for completion of this activities / materials.
CPE Provider #GE012
Global Contact Information:
For information about the accreditation of this activity, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and CMHC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Instructions for CME/CE Credit:
This activity is offered at no cost to participants. During the period December 15, 2017 through December 15, 2018, participants must follow these steps in order to receive CME/CE credit:
- Sign In or Register at https://www.cardiometabolichealth.org/my-account.html
- Read and accept the Terms & Conditions including the learning objectives and faculty disclosures.
- Complete the pre-test by recording the best answer to each question in the answer key. There is no scoring of the pre-test questions section.
- Review the educational activity.
- Complete the post-test by recording the best answer to each question in the answer key. Successful completion of the post-test is required to earn CME/CE credit. Successful completion is defined as a cumulative score of at least 70%.
- Complete the online evaluation form.
- After successfully completing the post-test and online evaluation form, your CME/CE certificate will be generated and will be available immediately for print.
Pharmacists Only: In order to receive credit, the ACPE requires that you provide your NABP ePID (6-10 digits) along with month and date of birth (MMDD) in the online evaluation. After completion of the evaluation via steps outlined above, record of your participation will be uploaded to the CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile. CMHC strongly encourages you to check your e-profile to ensure your credit is appropriately claimed.
For information about the accreditation of this activity, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Disclaimer:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Hardware and Software Requirements:
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.
